Product Description
Briquilimab is a targeted, humanized monoclonal antibody in development as a therapeutic to deplete diseased mast and stem cells as well as a conditioning agent to clear hematopoietic stem cells from bone marrow prior to transplant. By blocking signaling through the c-Kit receptor, briquilimab leads to depletion of diseased mast cells in the skin and diseased stem cells in the bone marrow. (Sourced from: https://www.jaspertherapeutics.com/jsp191/)
Mechanisms of Action: CD117 Binder
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: Fast Track - Severe Combined Immunodeficiency|Allogeneic Stem Cell Transplant|Hematopoietic Stem Cell Transplant|Stem Cell TransplantOrphan Drug - Stem Cell Transplant *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Jasper Therapeutics
Company Location: Western America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Germany, United States
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Jasper Therapeutics presented P2 Chronic Spontaneous Urticaria results on 2026-01-08 for Briquilimab
- Clinical Outcomes Reported - Jasper Therapeutics presented P1 Asthma results on 2025-12-02 for Briquilimab
- Clinical Outcomes Reported - Jasper Therapeutics presented P2 Asthma results on 2025-12-02 for Briquilimab
Highest Development Phases
Phase 2: Chronic Inducible Urticaria|Chronic Spontaneous Urticaria|Urticaria
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06736262 |
JSP-CP-014 | P2 |
Enrolling by invitation |
Urticaria |
2026-12-01 |
50% |
2024-12-17 |
Primary Endpoints|Treatments |
2023-505446-25-00 |
JSP-CP-011 | P2 |
Active, not recruiting |
Chronic Spontaneous Urticaria |
2026-05-31 |
2025-05-02 |
Treatments |
|
2023-507534-24-00 |
JSP-CP-010 | P2 |
Active, not recruiting |
Chronic Inducible Urticaria |
2025-12-22 |
2025-05-02 |
Treatments |
|
2024-517830-17-00 |
JSP-CP-014 | P2 |
Recruiting |
Urticaria |
2029-12-07 |
50% |
2025-05-02 |
Treatments |
NCT06162728 |
BEACON | P2 |
Active, not recruiting |
Chronic Spontaneous Urticaria |
2026-10-31 |
12% |
2026-01-23 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |